Aptamer Share Discussion Threads

[bri15] 02/10/2024 12:38

Newuncle is deramping now on LSE, he's an horrible f..ker.

[bri15] 02/10/2024 12:24

A ruler is afoot T2.

[turbotrader2] 02/10/2024 12:09

something afoot

[bri15] 01/10/2024 13:11

Well I know one thing,the share price is way,way too low and it's only a matter of time before it takes off,bit more volume or some news and we be away,I just topped up,no brainer this one.

[dplewis1] 01/10/2024 12:50

Lol .. account setup today ?

[bagpuss67] 01/10/2024 12:27

That's one hell of a specific ramp!

[bri15] 01/10/2024 12:25

Sorry Aptamers you have lost me,are you saying this company is getting bought out?

[aptamers] 01/10/2024 11:52

Rule 2.7 cash offer incoming - Molecular Partners AG (NASDAQ: MOLN) FINALISING offer conditions with advisors. Hopefully this satisfies existing holders, not JUST recent placement buyers.

[affc21] 01/10/2024 11:13

Worth reading Some very impressive medical technology, which now includes the Unilever cosmetic collaboration since the publication of the Admission to AIM document

[affc21] 01/10/2024 11:06

And also copied below, taken from the:Admission to AIM document (16 December 2021)6.     KEY ADVANTAGES OF APTAMER GROUP 6.1   Large growing market The antibody market is serviced by approximately 400 companies worldwide and its value is currently estimated at $145.7 billion per annum. The global market is expected to grow at approximately 11.31 per cent. (CAGR) to $249 billion by 2026. Of this, the research antibodies market accounted for circa $3.6 billion in 2020. Reports suggest that between 50-60 per cent. of available research antibodies fail to meet their internal research standards, implying a current market potential of ~$2 billion, without encroaching on the market of successful antibodies. This presents a significant market opportunity for companies with alternative binding technologies, such as the disruptive technologies used by Aptamer Group. The existence of this market opportunity is validated by the existence of several non-animal-based alternative affinity ligand platforms which have already been developed and commercialised. Several independent market reports predict that the aptamer market will grow at between 18 per cent. and 28 per cent. (most suggesting ~20 per cent.) CAGR, with predicted market values of between ~$5 billion and ~$9 billion by 2025. Increased investment in the sector has aided market growth and highlighted the benefits of aptamers compared to antibodies. Investment in the aptamer market is predicted to increase as their superiority is further recognised and aptamer technology is increasingly adopted as an alternative to antibodies. Further, rising awareness of diseases such as COVID-19 that require rapid affintiy ligand development to support diagnostics, vaccines and medicines and an increasing demand for aptamer-based diagnostics and therapeutics will aid the growth of the market. 6.2 Automated high throughput discovery platform Aptamers and Optimer® binders are isolated using the Group's proprietary high throughput liquid handling robotic systems. These systems give the Group significant capacity and throughput without the need for a large team of laboratory staff. Using high throughput liquid handling systems, a relatively small team of scientists can isolate aptamers against up to 36 protein targets simultaneously, in as little as 10 working days. The Board believes this capacity is unparalleled amongst the Group's competitors. The key capabilities of the Group's proprietary high throughput systems are listed below:# the Group's scientists operate in specialist teams, using a distinct, highly automated process to address different target types (e.g., proteins, small molecules and cells), enabling a broad process application;# an increased likelihood that aptamers will perform as required, due to incorporation of customers' 'end application' conditions in the automated development processes;# increased reliability and higher success rates, as automation removes human error and variability from aptamer development processes;# parallel processing under different conditions increases the likelihood of identifying aptamers, which leads to improved screening success rates of more than 70 per cent.;# capability for rapid turnaround and high capacity from proprietary automated aptamer development platforms;# the bespoke integrated platform is the result of extensive proprietary know-how and intellectual property and is therefore difficult and expensive for others to replicate; and # the modular automated platforms can be readily scaled to increase capacity. 6.3 Aptamer binding profile is tailored to customer needs and application In the in vivo development of antibodies, there is almost no opportunity to control the process once a target is introduced to an animal host. Antibody isolation, therefore, has a critical weakness that often leads to the isolation of antibodies that bind to unintended targets, leading to inaccurate results from research applications or the developed diagnostic tests, poor assay reliability or reproducibility and an increased potential for 'off-target' effects if the antibody is used during therapeutic development. This can to some extent, be ameliorated using techniques such as affinity maturation, but does not guarantee that suitable molecules with appropriate binding properties will be developed. In the development of aptamers, the process can be precisely controlled and therefore leads to a better outcome with less requirement for downstream optimisation. During the aptamer selection cycle, counter-selections steps are introduced, in which the aptamers are exposed to targets that the aptamer must not bind to (e.g., a related protein that may interfere with a diagnostic test). Any aptamers which bind to these unwanted targets are removed from the population, leaving only aptamers that do not bind to this unwanted target. In vitro selection of aptamers, therefore, allows for more precise control over the conditions under which the aptamers interact with the target. The Group's scientists replicate the environment required for the end-use application as closely as possible during selection. For example, if a customer wishes to develop a bedside assay to detect a disease-associated protein in urine, Aptamer Group will isolate the aptamers at room temperature and in a 'mock urine' sample. These modifications help to ensure that the aptamer will function correctly in the final product and minimises downstream optimisation, saving time and development cost. Further, Aptamer Group has a 70 per cent. success rate of producing operative binding molecules, which has proven to be an obstacle for some companies, quoting less than a 30 per cent. success rate, The aptamer discovery process is an iterative loop of various stages, where the optimal binders firstly must be correctly identified prior to extraction. It is therefore most beneficial to extract the best binding aptamers in stage one, as then the population can be multiplied and the process can be re-run from these. The first stage is also the most difficult, as the pool of aptamers is also the largest. During the SELEX round, the Group's skill allows them to find binders with a high success rate. This was demonstrated in Aptamer Group's success of developing Covid-19 binders in 17 days, which the Board believes is materially faster than many competitors.6.4 Reliable manufacture, scalability and security of supply There are inherent advantages associated with manufacturing and scalability when using aptamers. Antibodies are typically produced in animals or cell cultures, which are comparatively difficult to control, leading to batch-to-batch variability and scaleup issues. By contrast, aptamers are synthetic and are produced using well-defined, controlled and easily scalable chemical processes. The Directors believe this is a significant advantage and opportunity for the Group. 6.5 Moral and ethical advantage Aptamers are totally synthetic, requiring no animal use at any stage of their development or manufacture, unlike antibodies. Aptamers are produced using well characterised and readily controlled (and scalable) chemical processes. This means that aptamers and Optimer® binders conform with and are supported under EU directive 2010/63/EU3 and the NC3Rs initiative. 

[affc21] 01/10/2024 11:04

Interesting reading as copied below, taken from the:Admission to AIM document (16 December 2021)5.     OPTIMER® BINDERS 5.1   Overview The Group has developed aptamer technology to produce a derivative known as Optimer® binders, which are a key competitive differentiator. The Group's proprietary Optimer® technology generates aptamer molecules with improved properties that function as an antibody alternative. The core binding region of the aptamer is identified, and unnecessary portions of the aptamer sequence are removed to leave the minimal functional fragment. Furthermore, the Directors have identified an opportunity to further develop the chemistry of Optimer® binders with enhanced functionality, currently known as OptimerPLUS, as shown in the diagram below (page 21):  (Figure 2: Illustration of the development of aptamer and Optimer® binders and relative size of molecules). As the resulting Optimer® binders do not contain any unnecessary sequences, they often have a more stable structure, meaning less structural rearrangement is needed upon target engagement, which generally results in improved binding properties compared to the full-length parent aptamer. When used in therapeutic applications, Optimer® binders have improved tissue penetration and access to binding sites which may be unreachable by larger molecules such as antibodies. This trimming process makes Optimer® binders approximately 50-60 per cent. smaller than the parental aptamer (~10kDa compared with ~30kDa) which gives a number of advantages including: #Greater yield during synthesis: As with any chemical process, solid-phase synthesis steps are not 100 per cent. efficient, meaning that a small fraction of the product is lost with each building block added to the growing chain. The synthesis of shorter Optimer® binders requires fewer coupling steps to complete, leading to lower losses and therefore greater final yield of full-length product.#More cost-effective production: The inefficiencies in the aptamer production process can lead to the loss of a proportion of the manufactured material. This reduces the cost-effectiveness of longer oligonucleotides relative to shorter oligonucleotides. It must be noted that even with these losses, both aptamer and Optimer® production is still significantly more cost-effective than antibody manufacture (on a mole to mole basis).#Increased tissue penetration for targeted therapeutics: The comparative size difference of aptamers, and Optimer® binders particularly, compared to antibodies (~10kDa – 30kDa for aptamers, compared to ~150kDa for antibodies), allows aptamers and Optimer® binders to penetrate tissues more readily than larger molecules like antibodies. This is a significant advantage in treatment of conditions, such as solid tumours.#Interactions are closer to sensor surfaces giving better response in biosensors: In many biosensor platforms, there is a performance advantage to having the interaction with the target molecule occur as close to the surface as possible or a higher loading density of binders on the sensor surface. Optimer® molecules have smaller physical dimensions, meaning that the target interaction happens closer to the sensor surface, leading to improved signals. The smaller size of the Optimer® also allows for a greater packing density of the Optimer® on the sensor surface, which can lead to enhanced sensitivity. Optimer® binders enable faster development of research reagents, rapid diagnostic development and shorter time to clinical application of binders, due to the speed at which they can be developed and manufactured. This gives a faster route to market. Optimer® binders also have tuneable binding specificities and have scalable manufacturing capabilities with their advantageous batch-to-batch reproducibility, which enables better and cheaper diagnostics (through cost savings in development and reduced waste). Optimer® binders offer a significant advantage over other target binders used in small molecule detection assays, as they allow the detection and quantification of small molecules (and potentially proteins) in a simple, 'gain-of-signal' assay, using a single binding reagent.5.2 OptimerPLUSIn 2020, Aptamer Group acquired a patent portfolio covering a range of novel nucleotide chemistries that had had over 10 years of previous development work. This innovative hybrid technology platform combines the benefits of nucleic acid aptamers and protein-based binders (e.g., Affibodies, Nanobodies and Affimers), offering the potential to create enhanced binders with the chemical diversity of amino acid side chains, and the flexibility and tunability of aptamers – this group of molecules is currently known as OptimerPLUS binders. 

[affc21] 25/9/2024 18:46

Aptamer Group WebinarDeveloping Optimer vectors for precision targeting of RNA therapies:Dated 16.09.24https://youtu.be/sVL5-Jz5IboSite-specific delivery remains a significant challenge faced by novel RNA therapies. The use of cell or tissue targeting Optimer non-viral vectors can help to overcome the three major hurdles of: 1. selective targeting to specific cell types, 2. internalization of the RNA therapeutic payload to the target cell, and 3. ensuring the therapy is functional once in the cell. Watch this on-demand webinar to understand how we develop Optimers as therapeutic vectors that overcome each of these challenges, and how this can help advance your precision therapies. Learn how:Optimer development is tuned for selectivity to specific biomarkers and cell typesVectors are identified to ensure cell internalizationOptimer vectors for fibrotic liver show selectivity and effective knockdown with siRNA cargo

[dplewis1] 25/9/2024 16:06

I bought a mill of these earlier, hopefully see some progress soon. Worth a punt imo now funding sorted

[gepetto100] 25/9/2024 15:25

Theres no panic Everything in good time the company are set with wind in their sails for the next couple of years financially Ive confidence in the Doc to announce progress when the time comes Until then as Ive always said be patient If you cant good luck with your next venture

[npk2] 25/9/2024 13:57

The Company can't "hold off" announcing news because some are offloading their shares.They have to inform the market without delay, any price sensitive or major development that could lead to a substantial sheer price movement. Failure to comply could result in the Directors of the Company being prosecuted.It's more likely that they haven't announced anything because the have nothing to announce currently.

[bones698] 24/9/2024 14:21

Need some progress on contracts soon . They are probably holding off a bit as the churn stops before announcing news

[affc21] 19/9/2024 08:42

Try this:hTTps://www.pharmiweb.com/press-release/2024-04-15/aptamers-market-to-exceed-usd-130-billion-by-2032-fueled-by-biomedical-research-marketresearchb

[bri15] 19/9/2024 06:41

Sorry link won't work, posted it from LSE.

[bri15] 19/9/2024 06:40

hxxps://www.pharmiweb.com/press-release/2024-04-15/aptamers-market-to-exceed-usd-130-billion-by-2032-fueled-by-biomedical-research-marketresearchb

[gepetto100] 16/9/2024 13:20

MMS operating just under mid Some sells are buys GLA

[bones698] 16/9/2024 06:37

Good appointment from avacta says a lot

[affc21] 16/9/2024 06:14

https://www.voxmarkets.co.uk/rns/announcement/16049025-9e2f-41bf-912f-637bce1f96a0